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Summ~ary 
Fresh sera from mice immunized by bearing an immunogenic tumor or by repeated injections 
of aUogeneic spleen cells or xenogeneic erythrocytes powerfully suppress cytolytic T cell responses 
in one-way mixed lymphocyte cultures. Suppression is not antigen specific, though is mediated 
by immunoglobulin (Ig)G specific for the immunizing antigen. Suppression caused by IgG mimics 
that caused by active transforming growth factor B (TGF-B). IgG associates with or carries latent 
TGF-B; however, suppression caused by the complex of IgG-TGF-~ requires macrophages (Mck), 
whereas active TGF-/~ alone does not. Also, IgG dissociated  from TGF-~ does not cause suppression, 
suggesting that M~b may take up Ig-TGF-~, process the complex,  and deliver active TGF-B to 
lymphocytes. Indeed, suppression by immune serum was prevented by antibody to Fc receptors, 
by saturating Fc receptors with heterologous IgGs, and by antibodies against TGF-~. The overall 
findings reveal a previously unrecognized regulatory circuit whereby IgG produced in response 
to one antigen nonspecifically  downregulates cytolytic T lymphocyte responses to unrelated antigens. 
The findings introduce the intriguing possibility  that TGF-B delivered by IgG and processed 
by M~k may mediate important biological effects in processes such as wound healing,  tumor 
growth, and some autoimmune diseases. 
A  prior or dominant immunization of mice with one an- 
tigen abolished CD8 § cytolytic T lymphocyte (CTL) 1 
responses to a second unrelated antigen given simultaneously 
(1). Suppression became systemic and could be transferred 
passively to normal mice by fresh immune serum alone. In 
the present experiments,  fresh serum from such immunized 
mice in high dilution abolished CTL responses in one-way 
MLC, presumably in a way analogous to that occurring in 
vivo. The following experiments were designed to determine 
the nature of the serum components and the cells responsible 
for suppression of CTL in MLC. 
Materials  and Methods 
Mice and Cell Lines.  Donors of sera and lymphoid cells were 
C3H  (H2  k)  female  mouse  mammary  tumor  virus-negative 
(MTV-) pathogen-free mice 8-12 wk old and housed in a bar- 
tier facility; donors of allogeneic cells were BALB/C (H2  b) female 
mice also pathogen free and housed in a barrier facility. C3H SCID 
mice purchased from Imdyne (San Diego, CA) were Pneumocystis 
1Abbreviations used in this  paper: AD -, nonadherent cells; otSer, sera from 
immune mice; CTL, cytolytic T lymphocytes;  DC, dendritic cells; HRBC, 
horse red blood cells; Mqt, macrophages; NMS, normal mouse serum. 
carinii free and housed similarly. Tumor targets for measuring CTL 
in MLC were P815 (H-2  d) calls (see accompanying manuscript [1] 
for details). 
Immunizations and Murine Sera.  C3H mice under light ether 
anesthesia were injected in hind foot pads with 0.05 ml of 5% (vol 
cells/vol diluent) cell suspension of washed sheep or horse erythro- 
cytes (SRBC or HRBC); injections were repeated every other day 
four to six times; mice were bled 1 or 2 d after the last injection; 
i.e., 7-12 d after injections began. Sera from immune mice (c~Ser) 
were pooled from three or four identically injected mice and used 
within 72 h unless noted otherwise. Normal mouse sera (NMS) 
were obtained from nonimmunized mice of the same age and housed 
identically.  NMS and c~Ser were either untreated (Table 1, Exps. 
1 and 2) or diluted  1:10 in RPMI and separated into <100- and 
>100-kD  fractions by fihration/centrifugation  using  Centricon 
Microconcentrators (Amicon, Beverly, MA) for Exp. 3 (Table 1) 
and all subsequent experiments. Both the <100- and >100-kD frac- 
tions were reconstituted to the same volume as the sample before 
fractionation and were considered to be at a dilution of 1:10. 
Lymphocytes, Nonadherent Cells (Ad-), Dendritic Cells, and Cells 
without Macrophages,  Popliteal lymph node or spleen  cells were 
dispersed and washed in complete medium; debris and aggregates 
were  removed  by  gravity  sedimentation.  Ad-  were  incubated 
twice for 60 min with carbonyl iron (10  s ceils/10 ml medium/2 
grn carbonyl iron); ,,o95% of macrophages (M~) and dendritic ceils 
(DC) are removed by this procedure. Cells highly enriched for DC 
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cells/10 ml medium/10-cm culture plates) in an initial 2-h incuba- 
tion; nonadherent cells were removed and the volume restored. Most 
DC detach during an additional 18-22-h incubation while most 
Mq~ remain adherent; ,~2  x  105 detached cells are usually recov- 
ered per 10  s spleen cells and 60-80% of these cells are DC with 
most of the contaminating cells consisting of M~k. Ad- cells do 
not respond in MLC unless  restored by adding DC,  •3  x  104 
DC/5  x  105 responding lymphocytes being optimal. 
MLC and Assay.for Cytolytic T Cells.  MLC were 5  x  105 C3H 
(H2  k) normal spleen cells and 5  x  105 normal, irradiated (2,000 
rad) BALB/c (H2  a) spleen cells per well of 96-well flat-bottomed 
tissue culture plates (2). Cells were suspended  in 100/~1 of com- 
plete medium, which was: RPMI 1640 with 25 mM Hepes sup- 
plemented with 2 mM t-glutamine,  I mM sodium pyruvate, 0.1 mM 
nonessential amino  acids,  5  x  10 -s  M  2-ME,  and  10%  FCS; 
50 U penicillin  and 50/zg of streptomycin were added per 100 ml 
of medium. 100/xl of supplemented RPMI 1640 without FCS was 
added to each culture; this addition was either medium alone for 
control cultures or contained agents such as IgGs, TGF4~, etc. Thus, 
the final concentration of FCS was 5%, and concentrations or di- 
lutions of each additional agent are recorded per milliliter of the 
final 200/xl of culture medium. Cultures were incubated 4 or 5 d 
at 37~  5%  CO2,  and  100% humidity. Controls were six or 
eight replicate cultures to which medium alone was added;  each 
variable was tested in duplicate or triplicate cultures. Viable cell 
recovery was equivalent (less than twofold difference) in control 
and variously treated cultures. One-half of each culture (E/T cell 
ratio of ,~50:1) and seven additional double dilutions of each cul- 
ture were assayed separately against SlCr-labeled P815 (H2  a) target 
cells using 4-h SlCr release  assay (2);  each  culture was  assayed 
separately so that results are means for six to eight cultures con- 
taining medium only and two or three cultures for each variable 
tested. For convenience for comparing control and variously treated 
cultures, results are reported for only three fourfold dilutions or 
fractions of cultures assayed. Because the slopes of curves for lysis 
caused by different dilutions of cells from test and control cultures 
are rarely parallel, we have no adequate way for statistical  analysis 
of differences. Also, for this reason,  it is not strictly appropriate 
to convert results to lytic units, although we have done this to make 
comparing gross differences easier. For this purpose, a lytic unit 
is arbitrarily defined as the reciprocal of the fraction of identical 
cultures, rounded to the nearest 10, causing 30% lysis of labeled 
target cells. We only emphasize differences between test and con- 
trol cultures greater than fourfold whether indicated by comparing 
lysis at different fractions of  culture or by lytic units. Furthermore, 
all of the differences of this magnitude reported have been confirmed 
in two or more additional experiments, which are not reported. 
Treating responder cells before culture or treating cells harvested 
from MLC after 4 or 5 d incubation with anti-CD8 antibody and 
complement abolishes  CTL activated in this culture system (2). 
Secretion and Assay  for TGF-fl.  Lymphoid cells or a murine cell 
line designated 7.63, originally designated 1591-N-TGF-1, trans- 
fected to secrete murine latent TGF-/81 (3) were cultured in 5  x 
105 cells/ml of MEM containing 0.1% FCS at 37~  7.5% COs, 
and 100% humidity for 48 h. The medium alone contained <0.01 
ng active and <0.1 ng total TGF-B/ml. Supernatants were assayed 
without treatment to measure active TGF-B, and after acidification 
at pH 2.0 for 30 min, to measure total TGF-B. Secretion is recorded 
as ng/105  cells per 24 h using an assay dependent on inhibition 
of proliferation of cells from a line of mink lung "epithelial-like" 
cells, designated MvlLu (4). TGF-B is secreted as a latent complex 
of "~110 kD;  only the cleaved active 25-kD  homodimer binds 
receptors or is bound by the anti-TGF-3 antibodies we have. The 
assay does not discriminate between different isoforms of TGF-B, 
but neutralization of suppression by antibodies to TGF-/~ confirms 
that suppression  is mediated by TGF-/~, and antibodies relatively 
specific for different isoforms can indicate the form of active TGF- 
in a preparation using the MvlLu assay. 
Antibody Titers.  Sera were serially double diluted in PBS con- 
taining 0.5% BSA in 96-well V-bottomed plates.  For agglutinin 
titers, each well contained 50/~1 of  diluted serum and 50 #1 of  0.05% 
RBC; for hemolysin titers, each well contained an additional 50 
/zl guinea pig complement absorbed with SRBC and HRBC and 
diluted 1:20 in PBS; each sample was titered in duplicate for both 
agglutinin and hemolysin titers. Plates were incubated I h at 37~ 
and overnight at 5~  Titers were read using a magnification of 
3. The antibody titers are reported as the reciprocal of the highest 
serum dilution that caused gross agglutination or complete hemol- 
ysis of erythrocytes; duplicate titers did not vary more than one 
double dilution. Hemolysin titers are not reported separately but 
were equal to or one double dilution lower than agglutinin titers. 
Reagents.  Murine TGF-B1 was  the supranatant  of a murine 
tumor cell line transfected with cDNA for murine TGF-B1, desig- 
nated 7.63;  the supranatant contains ,~10 ng/ml of TGF-B after 
acid activation and virtually no active TGF-3 without acid treat- 
ment. Because both latent and active TGF-/~ adhere to plastic,  all 
samples are processed and stored in plasticware preincubated with 
1% BSA in saline. The total amount of TGF-/~ in such samples 
is stable during storage for many months. The following reagents 
were purchased:  porcine TGF-~I (pTGF/~) (lot no. BO60; R & D 
Systems, Minneapolis,  MN); monoclonal mouse anti-TGF-B2, B3 
(lot no. B1674; Genzyme, Cambridge, MA); TGF-B neutraliza- 
tion antibody, primarily for TGFB1 (Chicken)  (lot no.  W247; 
R & D Systems); normal chicken IgY (endotoxin flee) (lot no. U142; 
R & D Systems). Anti-Fc receptor antibody (rat anti-mouse mono- 
clonal FcR, designated 2.4G2) was a gift of Dr. J. Quintans (Univer- 
sity of Chicago); the supranatant and rat control Ig were prein- 
cubated with responding lymphocytes for 30 min before stimulator 
cells and immune sera were added to culture. Murine (m)IgG chro- 
matographically purified were purchased from Cappel, Organon 
Teknika Corp. (Durham, NC); and from Zymed Laboratories,  Inc. 
(San Francisco,  CA). Preparations of mlgs contained 0.05% Na 
azide, which was removed by repeated high dilution and reconcen- 
trating using Centricon 3 microconcentrators. Affinity-purified goat 
antibody to mouse Ig (IgG, IgA, IgM) was purchased from Cappel, 
Organon Teknika Corp. Rabbit IgG was affinity-isolated  antigen- 
specific antibody against horse spleen ferritin (Sigma Chemical Co., 
St. Louis, MO). Sterile sheep and horse blood in Alsever's solution 
was purchased from Environmental Diagnostics (Burlington, NC), 
and was used within 6 wk. 
Abso~tions of Sera.  Sera  were absorbed on Protein A-Sepharose | 
4 Fast Flow (Pharmacia  Fine Chemicals,  Piscataway, NJ); on pro- 
tein G using MabTrap  TM G and HiTrap  TM G (Pharmacia LKB Bio- 
technology, Uppsala, Sweden), and on affinity-purified  goat anti- 
body to routine Ig (IgG, IgA, IgM) coupled to CN-Br Sepharose 
4B (Pharmacia  Fine Chemicals), 1 mg antibody/ml of Sepharose 
beads.  Sera, diluted 1:10 in 0.2 M  NazPO4 and beads  (vol/vol), 
were constantly mixed for 75 min at 20~  The supranatants ob- 
tained  after centrifugation and  filtration were dialyzed against 
medium overnight. For absorption on heterologous erythrocytes, 
sera were diluted 1:25 in medium and absorbed (vol/vol) with packed 
erythrocytes for 10 min at 5~  with frequent mixing. The suprana- 
tant was obtained by centrifugat;.'on and the procedure was repeated. 
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Immune Sera Abolish CTL Responses in MLC.  We observed 
repeatedly that fresh NMS added to MLC at final dilution 
in culture of 1:50-100  had no significant effect on CTL re- 
sponses;  in contrast, fresh immune sera (ctSer) at these or 
higher dilutions abolished CTL responses.  In different ex- 
periments otSer were from: (a) mice bearing immunogenic 
tumors that had grown for 2 or 3 wk or were from mice 
that had recently rejected such tumors; or (b) mice bled 1-3 d 
after receiving three or more injections of allogeneic spleen 
cells or xenogeneic erythrocytes given every 2 or 3 d. These 
observations were confirmed in a single experiment (Table 
1, Exp. 1). We found repeatedly,  as in Table 1, Exp. 1, that 
uSer raised against xenogeneic erythrocytes were usually sup- 
pressive  at higher dilutions than were sera from mice im- 
munized by tumors or aUogeneic spleen cells. Partially for 
this reason, but also for convenience for presenting data, we 
report in the following experiments only results using sera 
from C3H mice immunized with xenogeneic erythrocytes, 
though the essential findings have been confirmed using sera 
from C3H mice immunized in these other ways and sera from 
two  other  strains  of mice  immunized  with  xenogeneic 
erythrocytes. 
Blood was as suppressive as serum (Table 1, Exp. 2), indi- 
cating that the process of  clotting does not activate or generate 
factors responsible for suppression.  For this experiment, 0.1 
ml of heart blood from a single normal or immune (five in- 
jections of SRBC) mouse was added directly to 4.9 ml of 
culture medium and cells were immediately removed by cen- 
trifugation. Serum was prepared from the remaining heart 
blood obtained from the same mice after allowing clot retrac- 
tion to occur at room temperature for 90 min. The experi- 
ment included blood and sera from a mouse injected identi- 
Table  1.  Suppression of CTL Responses in MLC by Immune Sera 
Cytotoxicity 
Percent  51Cr release 
Lytic 
Exp.  Addition*  Dilution  1/8'  1/32  1/128  units 
1  Medium  -  88  75  44  256 
NMS  1:100  81  70  34  256 
TBA Ser.  1:100  34  16  4  8 
otC57 Ser.  1:100  23  10  3  8 
c~Sheep Ser.  1:300  27  11  2  8 
2  Medium  -  100  90  59  512 
Normal blood  1:900  97  68  44  512 
ctSheep blood  1:900  18  19  10  8 
t~Sheep Ser.  1:900  5  5  12  <1 
3  Medium  -  80  59  23  128 
NMS  1:600  86  26  40  128 
otSheep Ser.  1:600  1  0  2  <1 
SCID Ser.  1:200  77  76  28  128 
SCID "ctSheep Ser."  1:200  86  83  43  128 
4  Medium  -  89  78  48  256 
c~Sheep Ser.  1:300  1  0  0  <1 
ctSheep >100 kD  1:300  1  0  0  <1 
otSheep <100 kD  1:300  96  92  68  >512 
* In Exp.  1, TBA ser. was  a pool from three C3H mice bearing immunogenic tumors, designated  PKO4L,  that  had  grown progressively  for 3 
wk and were "~1.5  cm in diameter,  o~C57 ser. was  a pool from three C3H mice each injected  in foot pads with 107 C57 spleen cells three times 
every 2 d and bled 1 d after  the final injection, olSheep Set.  was from mice injected identically  with 10  s SRBC and bled at the same time as mice 
receiving allogeneic cells.  See text for Exps.  3 and 4.  Sera were unfractionated  in Exps.  1,  2,  and 3. 
*Fraction of culture. 
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for immune anti-sheep blood and serum (data not shown). 
Fresh serum from SCID mice, whether untreated or injected 
repeatedly with SRBC as in Exp. 2, caused no suppression 
(Table 1, Exp. 3), suggesting that suppression was most likely 
due to a product of an immune response. 
In a single trial all suppressive activity of an aSer fraction- 
ated by gel filtration was recovered in fractions of >70 kD. 
In repeated trials  all  suppressive activity of different pools 
of o~Ser was recovered in the >100-kD fraction obtained by 
filtration/centrifugation  (Table 1, Exp. 4), and as in that ex- 
periment the <100-kD fraction usually stimulated responses 
two- to fourfold. To reduce complications caused by compo- 
nents in sera that may have contrary effects in MLC, all sera 
for  the  following  experiments  were  separated  by  filtra- 
tion/centrifugation  and  only the  >100-kD  fractions  were 
used,  except as noted. 
We observed repeatedly that sera from mice injected with 
antigen five or six times were more suppressive than sera from 
mice injected three or four times,  and that  suppressive ac- 
tivity of sera was often lost or decreased by more than a three- 
fold dilution when stored for I wk or more at 5 or  -20~ 
though we have not assessed  these variables systematically. 
To avoid such problems czSer were used within 48 h of bleeding 
in each of the following experiments, and each serum tested 
was the >100-kD  fraction of serum pooled from three or 
more mice injected five or six times with xenogeneic erythro- 
cytes and bled I or 2 d after the last injection. We have found 
subsequently that  the >100-kD  fraction of c~Ser stored at 
-80~  retains full suppressive activity for at least 6 wk. In 
each of the following experiments, aSer and each of the vari- 
ables were tested at two or usually three threefold serial dilu- 
tions; we report results for only the highest serum dilution, 
which caused >~10-fold suppression of CTL responses. 
IgG Specific for the Immunizing  Antigen  Causes Suppres- 
sion.  As shown in Table 2, Exps.  1 and 2, crSer absorbed 
on protein A, protein G, or goat anti-murine  Ig coupled to 
Sepharose no longer caused suppression. Protein A and pro- 
tein G bind predominantly IgG whereas the goat anti-rou- 
tine Ig should remove all isotypes. Indeed, considerable anti- 
SRBC antibody (IgM and IgA identified by ELISA; data not 
presented) remained after absorption on protein A or protein 
G, but not after absorption on the goat anti-murine  Ig. In 
recently completed experiments, absorption of aSer on goat 
anti-murine  IgG coupled to Sepharose was as effective in 
removing  all  suppressive  activity  as  absorption  on  goat 
anti-murine  Ig (IgM,  G, A), though  absorption on c~IgG 
did not remove all specific anti-RBC antibody, whereas ab- 
sorption on cdg did. Absorption of o~Ser on goat anti-mu- 
rine IgM coupled to Sepharose reduced antibody titers four- 
Table  2.  Absorption and Elution of Ig Causing Suppression 
Exp.  Additions  to cultures*  Absorption  on: 
Cytotoxicity 
Percent StCr release  Antibody titer 
1/8*  1/32  1/128  Lytic units  o~Sheep  aHorse 
1  Medium 
aSheep Ser. 
cr  Ser.  Protein  A 
ccSheep Ser.  c~mlg 
2  Medium 
aSheep Ser. 
aSheep Set.  Protein  G 
3  Medium 
c~Sheep Ser. 
~xSheep Set.  SRBC 
~xSheep Set.  HRBC 
4  Medium 
aHorse Ser. 
c~Horse Ser.  SRBC 
aHorse Set.  HRBC 
82  72  32  128  -  - 
2  3  0  4  960  - 
81  74  34  128  240  - 
82  71  39  128  0  - 
62  25  7  32  -  - 
14  2  1  <1  1,280  - 
71  30  9  32  400 
84  65  23  128  -  - 
0  1  1  <1  1,600  0 
76  53  23  128  0  0 
2  3  4  <1  800  0 
100  87  62  256  -  - 
8  12  6  <1  0  3,200 
27  16  0  8  0  3,200 
87  50  30  128  0  0 
* All sera were >100-kD fractions tested at dilutions  of 1:300 (Exps.  1 
dilutions as the unabsorbed  samples. 
tFraction of culture. 
and 2) and 1:200 (Exps. 3 and 4); absorbed samples were tested at the same 
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Absorptions of immune or normal sera on goat IgG coupled 
to Sepharose or on Sepharose alone did not alter antibody 
titers, increase CTL responses, or alter the capacity of c~Ser 
to suppress, indicating that absorptions did not introduce ex- 
traneous factors that  might  affect cultures.  It was unlikely 
that suppression was due to IgE since protein A removed sup- 
pressive activity, and heat inactivation  of otSer at 56~  for 
30 min did not reduce suppressive activity (data not presented). 
Together,  the results indicated  that  suppression was medi- 
ated by IgG. 
Table 2, Exps. 3 and 4, show that Ig directed against the 
antigen used to raise the immune serum was responsible for 
suppression; i.e.,  otSer raised against SRBC lost all specific 
antibody activity and all suppressive activity after absorption 
on SRBC but not after absorption on HRBC; similarly, o~Ser 
raised against HRBC lost all specific antibody activity and 
nearly all suppressive activity after absorption on HRBC but 
not  after absorption  on SRBC. 
Antibodies against TGF-~ Prevent  Suppression.  Nonantigen- 
specific, non-H2-restricted suppression caused by ctSer mim- 
icked suppression caused by active TGF-~ in several ways. 
Addition of 1.0-10.0 ng active pTGF-B1 or mTGF-~I to MLC 
powerfully suppressed CTL responses. Addition of this amount 
or 10x  more latent mTGF-~8 had no effect on CTL responses. 
Maximum suppression occurred when otSer or active TGFt8 
was added to MI.C during the first 24 h of culture; no sup- 
pression occurred when either  agent was added on days 3 
or 4 of culture. Also, both agents caused little or no suppres- 
sion of CTL responses using sensitized cells obtained from 
mice recently immunized with the same alloantigen as used 
in  the MLC. 
To test directly whether TGF-B might be involved, anti- 
bodies to TGF-B were added to MLC.  In repeated experi- 
ments a routine mAb against TGF-/~ 2,3 (IgG2b) at concen- 
trations  that  partially neutralized  the effects of 1.0-3.0 ng 
of active porcine or murine  TGF-~8 prevented  suppression 
caused by adding c~Ser to MLC (e.g., Table 3, Exp. 1). Con- 
trol IgG2b of unknown specificity added to cultures at the 
same or 3 x  the concentration of the anti-TGF-B antibody 
had no effect on CTL responses.  Also,  in repeated experi- 
ments, a chicken antibody against TGF-/31 at concentrations 
that neutralized  1.0-3.0 ng of porcine or routine TGF-~8 in 
MLC very effectively prevented suppression caused by c~Ser, 
(e.g., Table 3, Exp. 2). The chicken antibody against TGF-/3 
alone had no effect on CTL responses in MLC; however, the 
findings using chicken antibody have to be taken with reser- 
vation (and serve as a cautionary note) because the normal 
chicken Ig provided as a control caused bizarre effects on cells 
in MLC that we have not observed for the chicken antibody 
against TGF-~ or for any other additive we have ever used 
during  the course of a great  many experiments. 
Secretion of TGF-fl by Lymphocyte&  otSer might suppress 
CTL responses by stimulating ceUs in MLC to secrete TGF-B. 
For these experiments, secretion of TGF-B by lymphoid cells 
was compared with secretion by a routine cell line transfected 
Table  3.  Antibodies  against TGF-~ Prevent Suppression 
Cytotoxicity 
Percent  S~Cr Release 
Lytic 
Exp.  Additions  to cultures*  c~TGF-B Antibody*  1/8s  1/32  1/128  units 
Medium  0  80  62  25  128 
Medium  otTGF-32,3  82  66  31  128 
TGF-31*  0  19  8  8  <8 
TGF-3I*  ccTGF-32,3  40  18  12  16 
o~Ser  0  6  2  2  0 
otSer  c~TGF-32,3  70  42  14  64 
Medium  0  86  78  46  512 
Medium  aTGF-/31  81  74  40  512 
TGF-3I  0  19  6  2  8 
TGF-31  ccTGF-31  77  40  14  128 
~Ser  0  54  18  9  32 
otSer  olTGF-31  84  82  40  512 
* TGF-3 was active pTGF-31, 1.0 ng/ml (Exp. 1) and 3.0 ng/ml  (Exp. 2). otSer were at dilutions of 1:200 (Exp. 1) and 1:300 (Exp. 2). 
* Monoclonal murine anti-TGF-32,3 (IgG2b), 50 #g/ml (Exp. 1). Murine lgG2b of unknown specificity  used as a control at 50-200 #g/ml had 
no effect on responses in this or other experiments. Chicken anti-TGF-31, 30 #g/ml (Exp. 2); see text for discussion of chicken Ig control. 
S Fraction of culture. 
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TGF-/~/106 cells per 24 h (3). Under the same culture con- 
ditions unfractionated lymphoid cells or highly purified popu- 
lations of B or CD4 + cells secreted <1.0 ng TGF-B, but the 
addition  of 1%  murine  serum caused unfractionated  B or 
CD4 + cells to secrete 1.0-5.0 ng TGF-~/106 cells per 24 h. 
Stimulation of secretion of TGF-B was caused exclusively by 
the >100-kD fraction of sera. Secretion by B and CD4 + cells 
was always higher than for CD8 + cells. We found no com- 
plementation between populations that resulted in secretion 
of more TGF-B than could be accounted for by the separate 
populations. Adherent cells, predominantly MO but including 
DC, alone with or without added serum, did not secrete mea- 
surable amounts of TGF-B. We consistently found that su- 
pernatants of cells depleted of adherent cells and stimulated 
with serum contained more TGF-~ than supernatants of cul- 
tures that included adherent cells,  suggesting that adherent 
cells inhibited secretion or consumed TGF-B. Greater than 
90% of TGF-fl secreted by lymphocytes in cultures was la- 
tent and required acid activation for bioassay or causing sup- 
pression of CTL responses in MLC. Also, '~90% of the ac- 
tivity of the activated TGF-B was inhibited in the bioassay 
by chicken antibody-specific TGFB1  (data not presented). 
The essential findings found in many repeated experiments 
are shown in Table 4. Lymphocytes, including B cells, secrete 
significant amounts of latent TGF-~, and cells from normal 
mice secrete as much TGF-~ as cells from immune mice. Fur- 
thermore, normal sera were as effective as o~Ser in stimulating 
secretion of TGF-B. In other experiments (data not presented), 
Table  4.  Secretion of TGF-B by Lymphocytes 
Exp.  Lymphocytes  Serum*  TGF-~* 
B  Imm.  LN  -  0.6 
B  Normal spleen  -  1.0 
-  aSer  0.6 
-  NMS  1.0 
B  Imm.  LN  c~Ser  3.5 
B  Imm.  LN  NMS  3.4 
B  Normal spleen  c~Ser  3.0 
B  Normal spleen  NMS  5.5 
B  Imm.  LN  -  0.7 
CD4  Imm.  LN  -  0.3 
CD8  Imm.  LN  -  0.5 
ccSer  1.0 
B  Imm.  LN  c~Ser  5.0 
CD4  Imm.  LN  c~Ser  2.8 
CD8  Imm.  LN  c~Ser  1.1 
* All sera were at a dilution of 1:100 and were unfractionated. 
Total nanograms secreted/106  cells per 24 h; all preparations tested be- 
fore acidification  contained <0.1  ng active TGF-B. 
sera from SCID mice or olSer absorbed on protein G were 
also as effective as normal or immune  sera.  Thus,  it is un- 
likely that suppression of CTL caused by adding c~Ser to MLC 
is  secondary to  stimulation  of secretion of TGF-/~  by re- 
sponding cells. For this reason, we examined whether IgG 
in o~Ser might  carry TGF-B. 
TGF-~ Is Associated with or Carried by IgG.  Different in- 
dividual or pooled NMS or o~Ser contained  "~200-300 ng 
TGF-/3/ml;  >90%  of serum TGF-B was latent  and >90% 
of acid activated TGF-B in sera was neutralized by antibody 
to  TGF-BI.  We  found  no  consistent  differences  in  total 
amounts of latent or active TGF-~ in either whole or the 
>100-kD fractions of NMS or c~Ser. Absorptions to remove 
Ig from NMS or aSer consistently reduced serum concen- 
trations of TGF-~ by •25-50%.  The findings indicated that 
"~2.0-10.0 ng of TGF-B is carried per 1.0 mg IgG (assuming 
that  serum contains  '~20 mg IgG/ml of serum),  and each 
of two commercial preparations  of mlgG affinity purified from 
"normal" mouse sera did contain 3-5 ng latent TGF-B/mg 
IgG (Table 5). Neither of the commercial preparations at a 
concentration of 1.0 mg IgG/ml culture medium inhibited 
(or enhanced)  CTL responses. We then purified IgG from 
our NMS and o~Ser by absorption on protein G coupled to 
Sepharose,  washing  the  column  contents  with  10  vol of 
diluent,  pH 7.0,  and briefly eluating  absorbed IgG at pH 
2.7 for 1.5 min using a 1.0 M glycine-HC1 buffer. The neu- 
tralized  eluate from NMS contained  no measurable  active 
TGF-fl and '~5.0 ng latent TGF-~/mg IgG, which caused 
no suppression when added to MLC at  1.0 mg IgG/ml of 
culture medium.  In marked contrast, the eluate from olSer, 
containing  '~1.0 ng active and *30.0 ng latent TGF-B/mg 
IgG, abolished CTL responses at a dilution that added "~3.0 
/~g IgG and '~0.1 ng TGF-/5/ml of culture medium (Table 
5,  Exp.  3). 
IgG  Dissociated from  TGF-fl  No  Longer Causes Suppres- 
sion.  While IgG in olSer carried significant amounts of la- 
tent  TGF-B,  suppression by c~Ser appeared to be an order 
of magnitude greater than could be accounted for if all the 
carried TGF-~ was activated.  Indeed,  o~Ser acidified  at pH 
2.0 for 30 min no longer suppressed CTL responses at the 
same high serum dilution,  though acid-treated c~Ser at low 
dilutions that added 1.0-3.0 ng of the activated TGF-fl/ml 
of culture medium  did suppress,  and this  suppression was 
prevented by preincubation of the treated sera with antibody 
to TGF-~  (data not  presented). 
Acid treatment of olSer not only activated TGF-/~ but also 
dissociated it from IgG. This was shown by acidifying o~Ser 
and  fractionating  it  before neutralization.  This  procedure 
yielded all specific olSRBC or olHRBC antibody in the >100- 
kD fraction and all TGF-3 in the active form and in the <100- 
kD fraction.  The  acidification/fractionation  procedure did 
not cause any loss of complement-dependent  hemolytic ac- 
tivity, which requires the Fc portion of antibody molecules. 
Interestingly, fractionation of c~Ser after acidification  and neu- 
tralization yielded the same amounts of active TGF-3, but 
virtually all of the TGF-B was now recovered in the >100- 
kD fractions,  indicating that the activated TGF-/3 reaggregates 
846  A  First or Dominant Immunization Table  5.  IgG Carries TGF-~ 
TGF-/~/IgG* 
Suppression of 
Exp.  Preparation*  Source  Active  Total  CTL/mg IgGS 
ng/mg 
1  IgG (commercial)  NMS  0.5  5.0  None,  1.0 
2  IgG (commercial)  NMS  0.5  3.5  None,  1.0 
3  IgG Prot.  G eluate  NMS  0  5.0  None,  1.0 
IgG Prot.  G eluate  czSer  1.0  30.0  Complete, 0.01 
* Preparations tested before acidification (active) and after acidification (total). 
* Commercial murine IgG: Exp. 1 (Cappel Laboratories) and Exp. 2 (Zymed Labs., Inc.), see Materials and Methods. 
S Per milliliter of culture medium. 
possibly  with  itself and/or  other  large  molecules.  These 
findings for one experiment are shown in Table 6. Aliquots 
of olSer were either acidified for 30 min and fractionated be- 
fore neutralization or were treated with the same quantities 
of acid and base added simultaneously before fractionation. 
The >100-kD fractions of both samples had the same anti- 
body titers to SRBC but the >100-kD fraction of the acid- 
treated aliquot no longer suppressed effectively whereas the 
control aliquot did, suggesting that the combination of IgG 
and TGF-B in fresh immune serum may have to be in a par- 
ticular  or unique configuration  for suppression to occur. 
Macrophages Are Obligatory  for Suppression Caused by Im- 
mune Serum.  Two call types are obligatory for CD8 + CTL 
responses in MLC, CD8 + lymphocytes, and DC (5). Selec- 
tive removal in vitro of B lymphocytes, or in vivo of CD4 + 
lymphocytes or NK cells from populations of responder and 
irradiated stimulator cells, did not lower (and usually caused 
higher) CTL responses, and in each case c~Ser was fully sup- 
pressive (data not shown). In contrast, o~Ser caused no sup- 
pression in Ad- cultures but reconstituted with DC (Ad- 
+ DC) (Table  7, Exp. I),  though small  quantities  of  active 
pTGF-~ abolished  responses  in such  cultures  (Table  7, Exp. 
2). These findings were confirmed in similar experiments using 
different  o~Ser and  active  mTGF-/~  as  well  as  pTGF-B. 
IgG-TGF-B might stimulate M0 to secrete factors, including 
leukotrienes, prostaglandins,  nitric oxide, or cytokines, that 
could suppress lymphocyte function, but in an extensive se- 
ries of experiments we were unable to prevent suppression 
caused  by  otSer  with  indomethacin,  acetylsalicylic  acid, 
N-monoethyl-t-arginine,  TNF-c~,  IL-2,  or  selected  other 
cytokines, each tested at six concentrations over a 2-log range 
(data not  shown). 
Interference  with MO Function  Prevents  Suppression by Immune 
Sera.  Presumably M0 take up IgG-TGF-B via Fc receptors 
for IgG and,  as shown in Table 8,  Exp.  1,  a rat  antibody 
directed against murine Fc receptors partially prevented sup- 
pression by otSer. Also, rabbit IgG added to cultures prevented 
suppression by aSer in a dose-dependent manner  (Table 8, 
Table  6.  IgG Dissociated  from TGF-~ No Longer Suppresses 
Cytotoxicity 
Percent  Cr release 
Suppression by:*  Treatment*  1/8s  1/32  1/128  Lyric units  Antibody titer 
Medium  -  93  98  71  512  - 
otSer  Control  21  10  6  (8  2,560 
Acidification 
c~Ser  Neutralization  85  78  49  256  5,120 
* The dilution of (xSer was 1:300. 
* Acidification was at pH 2.0 for 30 rain with fractionation done before neutralization; control o~Ser was treatM with the same quantity of acid 
and base added simultaneously before fractionation. Results are for the >100 kD fraction. 
$ Fraction of culture. 
847  Stach and R~y~vley Table 7.  Macrophages Are Obligatory for Suppression Caused by Immune Serum but Not for Suppression Caused by Active TGF-~ 
Cytotoxicity 
Percent StCr release 
Kesponder and irradiated  Additional  TGF-B or 
Exp.  stimulator cells*  cells*  immune serums  1/8  II  1/32  1/128 
Lytic 
units 
1  Whole  0  0  65  37  14 
Whole  0  c~Ser  13  5  3 
Whole  DC  0  71  36  16 
Whole  DC  otSer  7  5  3 
Ad-  0  0  14  5  12 
Ad -  0  o~Ser  5  2  5 
Ad-  DC  0  87  62  34 
Ad-  DC  olSer  77  60  23 
2  Whole  0  0  73  46  17 
Whole  0  TGF-/~I  5  5  9 
Ad-  0  0  13  6  4 
Ad-  DC  0  73  37  15 














" 5  x  105 responder and 5  x  10  s irradiated stimulator cells, either whole or depleted of adherent cells (Ad-). 
* 3  ￿  104 C3H DC added per culture. 
S ccSer (1:300) or pTGF-B1 (3 ng/ml of culture medium). 
II Fraction of culture. 
Table  8.  Inte~rence with Fc Receptors Prevents Suppression by Immune Sera 
Cytotoxicity 
Percent SlCr release 
Exp.  Suppression  by:*  Additions*  1/8s  1/32  1/128 
Lytic 
units 
Medium  -  100  88  49 
c~Ser  -  20  6  0 
-  cxFc AB  96  77  33 
-  Ig control  100  78  38 
czSer  ~xFc AB  93  47  9 
c~Ser  Ig control  51  17  2 
Medium  85  80  62 
c~Ser  16  2  0 
-  Rabbit IgG (50/~g/ml)  87  75  65 
-  Rabbit IgG (150/~g/ml)  88  80  65 
cr  Rabbit IgG (50 #g/ml)  65  34  !3 













* Dilutions of r~Ser were 1:400 (Exp. 1) and 1:300 (Exp. 2). 
* In Exp. 1, the concentration of the oeFcAB was ~15 /~g/ml, and the rat Ig control ~10 x  the concentration of the c~FcAB. 
S Fraction of culture. 
848  A First or Dominant Immunization Exp. 2), presumably by saturating Fc receptors. In addition, 
various "particulate" and soluble antigens that are phagocy- 
tized or taken up by other means also prevented suppression. 
For example, adherent cells were obtained by removing nonad- 
herent cells after a 2-h incubation; the adherent cells were 
cultured alone or with a soluble antigen, Pc-KLH, 10 #g/ml 
of culture medium; the cells were incubated for 24 h and 
then washed thoroughly. These cells were compared with 
fresh adherent cells for restoring the capacity of otSer to sup- 
press cultures lacking adherent cells but with added DC, as 
was done in Table 7, Exps. 1 and 2. The fresh adherent cells 
again completely restored the capacity of otSer to suppress; 
suppression was less using the adherent cells incubated  for 
24 h alone (possibly because of interaction of adherent cells 
with protein antigens in FCS?) and o~Ser caused no suppres- 
sion using adherent cells incubated  with the antigen (data 
not presented).  Apparently,  prior or other engagement of 
MS as well as blocking Fc receptors may prevent these cells 
from taking up and/or processing IgG-TGF-B in otSer. To- 
gether, the findings suggest that suppression is not due to 
"activated Mck;" e.g., Mck stimulated with thioglycolate or 
lectins for I>24 h that have many altered activities, including 
secretion  of TGF-/3 (6). 
Discussion 
Fresh homologous sera are often "toxic" for many culture 
systems; the fact that our sera came from pathogen-free mice 
may account for why 1-2% NMS did not suppress cultures 
and allowed us to study components in immune serum that 
do suppress CTL responses. Though our immune sera were 
obtained from intensely immunized mice, immunization was 
meant to be comparable to the antigenic challenge that might 
occur with growing tumors or infectious agents. Adjuvants 
were not used and all of our sera were obtained within 6-12 d 
of the first injection of antigen; thus, we do not think our 
results are an artifact of an unphysiological regime for im- 
munization. Though we have not studied the variables of 
antigen dose or injection schedule systematically, we have ob- 
served that serum obtained 7 d after a single injection of an- 
tigen was much less suppressive than sera from mice receiving 
the same total dose of antigen given every 2 d for three in- 
jections. 
Repeated antigen injections should favor formation of cir- 
culating antigen-antibody complexes that are taken up by 
MO and can cause various immunologic effects (7-9). Our 
c~Ser may well contain complexes present in great antibody 
excess and such complexes could play a role, though we have 
been unable to reproduce suppression with complexes formed 
in vitro over broad ranges of antigen-to-antibody  ratios using 
various  purified  specific antibodies  and appropriate  soluble 
or particulate antigens.  Also, heat-aggregated IgGs, which 
reproduce many of the effects of complexes, did not cause 
suppression of CTL responses, and storage of sera that favors 
aggregation of IgGs caused immune sera to lose rather than 
gain suppressive activity. IgGs are dissociated from antigens 
and other ligands by acidification; brief acid elution of IgGs 
from fresh immune sera absorbed on protein A or protein 
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G yielded duates that were fully suppressive. Acidification, 
pH 2.0 for 30 min should be more effective in dissociating 
antigen-antibody complozs, but this procedure also dissociates 
Ig and TGF-B, which may be the more critical effect of acid 
treatment. These arguments are supported by recent prelim- 
inary observations that indicate that suppression can be medi- 
ated by a <300-kD fraction of o~Ser that would exclude an- 
tigen-antibody complexes formed in great antibody excess, 
but the findings obtained to date do not rule out that sup- 
pression can be caused by a >300-kD fraction  of c~Ser. 
Our interest in the role of TGF-~ originally arose because 
active TGF-~ suppresses activation and proliferation of  resting 
lymphocytes (10-14); glioblastomas and selected  other tumors 
secrete latent TGF-~ and are associated with immune sup- 
pression (15-17), and an immunogenic murine tumor trans- 
fected to secrete latent mTGF-/~ failed to stimulate CTL in 
vivo and in vitro (3). Though the experiments presented here 
do not prove that TGF-B carried by IgG in c~Ser is respon- 
sible for suppression of CTL responses, we think the infer- 
ence is strong and the concept important enough to be con- 
sidered until confirmed or refuted. 
Ongoing studies are designed to determine whether sup- 
pression by otSer is caused by a particular  subclass of IgG 
and whether IgG and TGF-B are secreted as a complex or 
combine after secretion. Latent TGF-B of--110 kD is cleaved 
to yield the active 25-kD homodimer but the physiological 
process for activating TGF-B is not understood, though it 
is accomplished in the laboratory with various proteolytic 
enzymes (18) and most usually by acidification. This proce- 
dure requires  pH  2.0  for >15  min;  relatively little active 
TGF-/3 is obtained at higher pH or during shorter periods 
of acidification. The inactive portion of latent TGF-~ has 
at least three glycosylation sites that are necessary for latency 
(19); thus, it is tempting to think that IgG and TGF-B may 
be linked through carbohydrate chains that are cleaved or 
digested at target sites, e.g., by Mc#, causing activation of 
the carried TGF-~. Possibly the structure of the linkage be- 
tween TGF-B-IgG in fresh serum may alter on storage or 
manipulation to account for the lability of suppressive ac- 
tivity of otSer, since the total amount of assayable TGF-/3 in 
otSer remains stable during storage. 
Since IgGs and latent TGF-B are of comparable molecular 
mass, only a very small fraction of IgG molecules in olSer 
must carry TGF-B. However, even a few nanograms of TGF-B 
per milligram of IgG has the potential for producing impor- 
tant biological effects  if TGF-B can be delivered, concentrated, 
and activated at precise sites. M~k focusing  the activity of 
TGF-B delivered by IgG through Fc receptors may explain 
why TGF-/3 associated with IgG is an order of magnitude 
more effective in suppressing CTL responses than free active 
TGF4t added to cultures,  and may account for difficulties 
using antibodies against TGF-/3. Antibodies to TGF-/3 neu- 
tralize only active TGF-~ and are effective in bioassays only 
when they are preincubated with active TGF-/3 before addi- 
tion to target cells because of the higher affinity of active 
TGF-/~ for receptors than for antibody. Thus, in MLC, anti- 
bodies to TGF-~ may have different access to TGF-/3 in the 
cell-cell interaction or diffusion-limited  space between MO and lymphocytes depending on the form of the antibody. For 
example, this may explain why a murine mAb against TGF- 
B1,2,3 (subclass IgG1) does not prevent suppression (data not 
presented), whereas a murine mAb against TGF-B2,3 (sub- 
class IgG2b) does (Table 3). Possibly the subclass of antibody 
against  TGF-B  may be more critical  than  the  epitope on 
TGF- . 
We have confirmed that the mAb against TGFB2,3 does 
not neutralize m  or pTGF-~I in the MvlLu bioassay; how- 
ever, the same antibody does partially neutralize suppression 
of CTL responses in MLC caused by pTGF-B1 or c~Ser (Table 
3). The different isoforms of TGF-B undoubtedly share epi- 
topes, and receptors for TGF-B are probably not identical on 
MvlLu cells and murine lymphocytes. For these reasons, we 
do not think it surprising that an antibody that neutralizes 
the interaction of one isoform of TGF-B with receptors on 
cells in one system will necessarily be effective in another system 
and vice versa. Different considerations limit the use of other 
antibodies against TGF-B in MLC. For example, we cannot 
use rabbit antibodies because control rabbit IgG is as effec- 
tive as rabbit anti-TGF-B antibody in preventing suppression 
by otSer, undoubtedly because rabbit IgG blocks or saturates 
Fc receptors. Nevertheless, we interpret our overall findings 
as consistent with the idea that suppression caused by o~Ser 
is mediated by TGF-B1. 
On a broader scale,  the effects of TGF-3 are pleiotropic 
and depend on the type and state of activation or maturation 
of target cells in many different tissues (20-24),  suggesting 
that the activity of TGF-fl must be highly restricted or regu- 
lated at different sites. Thus, the idea that the activity of TGF-fl 
in immunity is modulated by Ig suggests one kind of strategy 
for limiting  the activity of TGF-fl to the relevant  system, 
just as the association of TGF-fl-2 with c~-fetal protein (25, 
26) suggests a different strategy for limiting activity of TGF-fl 
to the site of maternal-fetal interaction. Thus, IgG localizing 
TGF-fl at antigenic sites could play an important role in the 
homeostasis of immunity by augmenting proliferation of al- 
ready activated dominant lymphocyte clones (27), promoting 
isotype switch (27-29), suppressing activation/proliferation 
of new specific antigen-reactive clones that may arise during 
ongoing immunity, and suppressing some autoimmune dis- 
eases (30). On the other hand, TGF-fl can promote abnormal 
scarring  as well as wound healing  (31-37),  and  stimulate 
growth of some malignancies (38-41), so that antibody car- 
rying TGF-fl to antigen target sites in some autoimmune dis- 
eases or cancer may have deleterious effects. In an analogous 
way, desirable or adverse effects of specific antibodies given 
passively for experimental or clinical objectives (42) may de- 
pend on the presence and nature of TGF-fl carried by IgG. 
Thus,  the finding  that  IgG can carry biologically effective 
TGF-fl has  many important  implications. 
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